PR Newswire/Les Echos/
Sanofi Appoints Dr. Gary J. Nabel as Chief Scientific Officer
Paris, France - November 14, 2012 - Sanofi (EURONEXT : SAN ; NYSE : SNY) is
pleased to announce today the appointment of Dr. Gary J. Nabel, M.D., Ph.D.,
Senior Vice President, Chief Scientific Officer and Deputy to the President for
Global R&D, effective December 3, 2012. Dr. Nabel will report to Dr. Elias
Zerhouni, President, Global R&D, and will join the group's Global Leadership
Team. He will be based in Cambridge, Massachusetts.
Dr. Nabel joins Sanofi from the National Institutes of Health, where he served
as Director of the Vaccine Research Center (VRC) of the National Institute of
Allergy and Infectious Diseases since 1999. During his tenure at the NIH, Dr.
Nabel provided overall direction and scientific leadership of the basic,
clinical, and translational research activities of the VRC and guides
development of novel vaccine strategies against HIV and other emerging and
re-emerging infectious diseases, including Ebola/Marburg hemorrhagic fevers,
influenza, chikungunya and other viruses.
"Dr. Nabel's impressive scientific record and experience will be extremely
valuable to the Group", declared Christopher A. Viehbacher, Chief Executive
Officer, Sanofi. "I am confident that with his leadership, we can drive R&D
further towards tomorrow's breakthrough discoveries."
In his new position, Dr. Nabel will be responsible for assessing and
coordinating Sanofi's scientific direction for biopharmaceuticals, vaccines and
animal health with a focus on improving translational approaches across Sanofi.
In his role, he will lead the evaluation of scientific quality of projects and
programs across all of R&D, and participate in setting Sanofi's overall strategy
"I am very excited that Dr. Nabel will join Sanofi's R&D organization", said Dr.
Elias Zerhouni, President, Global R&D, Sanofi. "Our challenges today require
that we re-invent our R&D model. Gary's experience will be invaluable to help us
achieve this goal."
"I am honored and excited to join Dr. Zerhouni and the Sanofi team", said Dr.
Gary Nabel. "By strengthening our scientific base, we hope to accelerate the
rational development of innovative treatments that will save lives and improve
Dr. Gary J. Nabel Biography
Dr. Nabel has an extensive and distinguished background of academic and hospital
appointments, and committee memberships including numerous prestigious awards
and honors and an extensive publication record. He graduated magna cum laude
from Harvard College in 1975 and continued his graduate studies at Harvard
University, completing his Ph.D. in 1980 and his M.D. in 1982. He served as a
postdoctoral fellow in the laboratory of David Baltimore at MIT's Whitehead
Institute. Before his appointment at the Vaccine Research Center, Dr. Nabel
served as the Henry Sewall Professor of Internal Medicine, Professor of
Biochemistry, and Howard Hughes Medical Institute Investigator at the University
of Michigan in Ann Arbor. In addition to his faculty positions, Dr. Nabel also
served as the Director of the Center for Gene Therapy and co-director of the
Center for Molecular Medicine at the University of Michigan. In recognition of
his expertise at the forefront of virology, immunology, gene therapy, and
molecular biology, Dr. Nabel was elected as a member of the Institute of
Medicine of the National Academy of Sciences in 1998.
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT:
SAN) and in New York (NYSE: SNY).
Media Relations Investor Relations
Jean-Marc Podvin Sébastien Martel
Tel.: + (33) 1 53 77 46 46 Tel.: + (33) 1 53 77 45 45
The content and accuracy of news releases published on this site and/or
distributed by PR Newswire or its partners are the sole responsibility of the
originating company or organisation. Whilst every effort is made to ensure the
accuracy of our services, such releases are not actively monitored or reviewed
by PR Newswire or its partners and under no circumstances shall PR Newswire or
its partners be liable for any loss or damage resulting from the use of such
information. All information should be checked prior to publication.
-0- Nov/14/2012 15:09 GMT
Press spacebar to pause and continue. Press esc to stop.